Banka BioLoo Q4FY26 Results: Revenue Up 29% YoY to ₹18.02 Cr, PAT Turns Positive
Banka BioLoo Limited reported a strong Q4 FY26 with revenue up 29% YoY to ₹18.02 Cr and PAT turning positive at ₹157.1 Lakhs. Full-year PAT also turned positive at ₹38.2 Lakhs. The company's 12-month order book stands at ₹107 Crore, with significant contributions from both Railways and WaSH segments.
The substantial improvement in financial performance, including a turnaround from losses to profits and significant revenue growth, is a material development for the company and its investors.
The company reported a significant turnaround in profitability with positive PAT and EBITDA for both the quarter and the full year, alongside revenue growth. This indicates a strong recovery and positive financial performance.
Banka BioLoo Limited (BBL) announced its financial results for the quarter and year ended March 31, 2026. The company reported a significant turnaround in profitability, with a positive Profit After Tax (PAT) of ₹157.1 Lakhs for Q4 FY26, compared to a loss of ₹172.9 Lakhs in the same quarter last year. Full-year PAT also turned positive at ₹38.2 Lakhs, a substantial improvement from a loss of ₹929.6 Lakhs in FY25.
Revenue from operations for Q4 FY26 increased by 28.0% year-on-year to ₹1,802.3 Lakhs (₹18.02 Crore), while full-year revenue grew by 8.7% to ₹5,975.8 Lakhs (₹59.76 Crore). EBITDA also swung to positive territory, with ₹254.1 Lakhs in Q4 FY26 and ₹407.9 Lakhs for the full year, a marked improvement from losses in the previous year. This turnaround is attributed to cost optimization measures and higher execution in the WaSH segment.
The company's order book remains robust, with a 12-month order book of ₹107 Crore. The Railways business has an unexecuted order book of approximately ₹38 Crore, while the WaSH segment has an unexecuted order book of approximately ₹69 Crore, with new orders worth ₹16 Crore secured in Q4 FY26. Notable contract wins include expansions into Bangalore and Mumbai with projects from Brigade, Reliance, and RMZ, as well as multiple wins from Grade-A developers in Hyderabad.
What to do with a filing like this
Banka BioLoo Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Banka BioLoo Limited. Read the original for the full detail.